Goldman Sachs Group Inc.’s alternative investment arm has agreed to buy a majority stake in Dutch generic drugmaker Synthon from BC Partners.
Dublin, Dec. 16, 2024 (GLOBE NEWSWIRE) -- The "Companion Diagnostic Collaboration and Licensing Deals 2010-2024" report has been added to ResearchAndMarkets.com's offering. Companion Diagnostic ...
BC Partners has agreed to sell its majority stake in Synthon to Goldman Sachs Alternatives. Synthon is an international pharmaceutical company, with a platform specialized in developing, manufacturing ...
Goldman Sachs Asset Management (GS) is nearing a more than EUR 2B deal to buy drugmaker Synthon from BC Partners, people familiar tell the ...
Goldman Sachs Asset Management has agreed a more than €2bn deal to acquire drugmaker Synthon from BC Partners, according to people familiar with the matter, as it hopes to capitalise on demand for off ...
Goldman Sachs’ asset arm is in the process of acquiring the Dutch pharmaceutical company Synthon International for 2 billion ...
BC Partners is nearing a deal to sell Dutch generic drugmaker Synthon International Holding BV to Goldman Sachs Asset ...
Dec. 5, 2024 — Mangroves have been shown to provide $855 billion in flood protection services worldwide, according to a new ... Dec. 4, 2024 — Coconut palms are king throughout the tropics ...
Dec. 2, 2024 — Eating a diet with a higher ratio of plant-based protein to animal-based protein may reduce the risk of cardiovascular disease (CVD) and coronary heart disease (CHD), according to ...
The slowdown is worrying for the Kremlin but not serious enough to significantly hobble its war effort. By Anatoly Kurmanaev While support for Vladimir V. Putin’s threats resounded in pro-war ...
The role of computational tools in drug discovery and development is becoming increasingly important due to the rapid development of computing power and advancements in computational chemistry and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback